Brokerages Set Q32 Bio Inc. (NASDAQ:QTTB) PT at $12.17

Q32 Bio Inc. (NASDAQ:QTTB) has received a consensus recommendation of “Hold” from the nine ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $12.1667.

A number of brokerages have issued reports on QTTB. Weiss Ratings reissued a “sell (e+)” rating on shares of Q32 Bio in a report on Saturday, September 27th. Wall Street Zen raised shares of Q32 Bio from a “sell” rating to a “hold” rating in a research note on Friday, October 3rd.

Institutional Investors Weigh In On Q32 Bio

A number of large investors have recently modified their holdings of QTTB. Ameriprise Financial Inc. bought a new stake in shares of Q32 Bio during the 4th quarter valued at about $53,000. Two Sigma Investments LP bought a new stake in shares of Q32 Bio during the 4th quarter valued at about $183,000. Squarepoint Ops LLC bought a new stake in shares of Q32 Bio during the 4th quarter valued at about $65,000. Public Employees Retirement System of Ohio bought a new stake in shares of Q32 Bio during the 4th quarter valued at about $26,000. Finally, Nuveen LLC bought a new stake in shares of Q32 Bio during the 1st quarter valued at about $92,000. Institutional investors own 31.32% of the company’s stock.

Q32 Bio Stock Up 10.2%

Shares of Q32 Bio stock opened at $3.57 on Monday. The firm has a market cap of $43.55 million, a PE ratio of -0.83 and a beta of 0.11. Q32 Bio has a 12-month low of $1.35 and a 12-month high of $53.17. The company’s fifty day simple moving average is $1.95 and its two-hundred day simple moving average is $1.85.

Q32 Bio (NASDAQ:QTTB) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.36. As a group, sell-side analysts expect that Q32 Bio will post -12.32 earnings per share for the current fiscal year.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.